slot real money

Iowa's O hopes to stay hot vs. defense-minded Northwestern

Pooches in pullovers strut their stuff at London's canine Christmas sweater parade

ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.

Minnesota will try to bounce back from two straight losses when it hosts Bethune-Cookman on Sunday afternoon in Minneapolis. The Golden Gophers (5-3) are coming off a 57-51 loss against Wake Forest on Friday, which followed a 68-66 overtime loss against Wichita State on Thursday. Both games took place at the ESPN Events Invitational in Lake Buena Vista, Fla. Minnesota coach Ben Johnson cited inconsistency on offense as the main reason for his team's recent skid. "We're painfully figuring that out," Johnson said. "I thought our defense, though, (Thursday and Friday) has proven this is a top-40 or top-30 defense. We've got to be able to show up with offense and free throws." Golden Gophers starter Lu'Cye Patterson said he and his teammates remain confident in their potential as the Big Ten conference season approaches. "We just have to keep doing what we're supposed to do and keep our level of defensive play up," Patterson said. "It's going to win us a lot of games. The offense is going to come." Bethune-Cookman (2-5) will try to play spoiler on the road. The Wildcats have split their past two games as they beat North Dakota 79-67 on Tuesday and lost to Gardner-Webb 79-64 on Wednesday, both games played in the Cancun Challenge in Cancun, Mexico. Four players for Bethune-Cookman scored in double digits in their most recent game. Reggie Ward Jr. and Daniel Rouzan led the way with 14 points apiece, Trey Thomas scored 13 and Brayon Freeman chipped in 10. Bethune-Cookman is coached by Reggie Theus, who enjoyed a long NBA career and coached the Sacramento Kings for parts of two seasons. Theus said the Wildcats were in better position to compete this season compared with a season ago. "We've got a lot of depth, and we have age and experience," Theus said. "One of the biggest differences in our team is that we have great size now, where last year we were pretty small." Dawson Garcia leads Minnesota with 18.6 points and 7.3 rebounds per game. Patterson is next with 10.1 points per contest. Bethune-Cookman is led by Freeman, who is averaging 15.9 points per game. Thomas (11.7 points per game) and Ward Jr. (11.0) also are scoring in double digits. --Field Level MediaNumber of seats: 3 Seats filled: 1 8pm: In Count 4 of the Dublin Fingal West constituency, Sinn Féin's Louise O'Reilly was the first to be elected. There were tears of joy as she hugged her team and family members in the count centre. Sinn Féin's Louise O'Reilly secured a seat in this count, receiving a total of 8,261 votes after redistribution. Sinn Féin's Louise O'Reilly is elected on fourth count 7pm : At Count 3, two candidates were eliminated: Brynn Edwards (PBP) and Joe O'Brien (GP). There were 239 non-transferable papers during this count. Candidates' Performance in Count 3: 6pm: Count 2 for the Dublin Fingal West constituency has concluded with Sinn Féin’s Louise O’Reilly still in front and likely to be elected on the third count. Aontú's Robbie Loughlin has been eliminated. Second count results with redistribution of votes: 5pm: In the first count for the Dublin Fingal West constituency, the electorate consisted of 51,403, and the total poll saw 30,285 votes cast. Out of these, 168 votes were spoiled, leaving a valid poll of 30,117 votes. The quota required to be elected in this count was 7,530 votes. No candidates were elected during this count. From Count 2 onwards, the redistributed votes will come from the eliminated candidates. These include votes from Mark Joseph Parsons (IP), Oghenetano John Uwhumiakpor (Independent), John Oakes (IFP), and Ben Gilroy (Liberty Republic). In terms of vote distribution, the candidates' results in Count 1 are as follows: SF’s Louise O'Reilly and FG’s Grace Boland are leading the pack the pack, while other candidates, such as John Oakes, Mark Joseph Parsons, and Oghenetano John Uwhumiakpor, will be eliminated in Count 2 and their votes will be redistributed. 4.10pm: Rumour has it that results from the first count for Fingal West are due in around 30 minutes. 4.05pm: Sinn Féin’s Louise O’Reilly has said she is “very pleased” with how things are looking so far. The outgoing TD looks set to repeat her 2020 general election performance and top the poll and become the first elected in her constituency. "We had a lot of people who were ringing the office and saying, 'Look, when can I vote for you?' which is always a good sign,” she said. "But also there was a real, real mood for change, a real appetite for change on the doors. And I think that's what was reflected in the vote. "I'm very pleased with today’s tally indicators similar to my 2020 vote, which many people said was a flash-in-the-pan that wouldn't be repeated, well it has been repeated. "My vote held up, and it did so because of my party, I think, but also because of the work I do. "It's always tough in a three-seater, it's a completely different prospect to a five-seater. I'm just delighted,” she added. Sinn Féin's Louise O'Reilly said she is glad that she proved her 2020 topping of the poll wasn't a 'flash in the pan' moment 3.40pm: Still no announcement on first counts 3.20pm: It was announced that adjudication would take place at 3.30pm 2.30pm: Green Party TD and Minister of State with responsibility for Community Development and Charities Joe O’Brien has said that “It’s not going to be a good day for the party”. Judging by latest tallies he is clearly going to lose his seat in the constituency with just 6.2pc of first preference votes. In the 2024 elections tallies have showed he has roughly 1,793 first preference votes so far in comparison to the 8,400 first preference votes he got on the first count back in 2020. Speaking to the Irish Independent at the National Show Centre in Swords he thanked his campaign team for the hard work over the past couple of months. 'I've lost my seat anyway' says outgoing Green Party TD Joe O'Brien "We put an awful lot of work in... we are walking away, a lot of us with essential achievements, and that's what we're gonna hang on to,” Minister O’Brien said. "We hope we retain some few seats so that a lot of the things that we've got done... don't get that slip away in the next door, that would be our concern. "I've lost my seat anyway, and that's very disappointing from my point of view. But as I said, you know, we put a lot of work in,” he added. He said that the redrawing of the constituency definitely hindered his likelihood to retain his seat “losing half of his base”. "We knew that risk, and that's, that's politics, that's the way it goes. Sometimes it seems to be that that's continuing to be the pattern in Irish politics,” he said. "If you're given a mandate by the people, I think you have a responsibility to step up to the place and follow through, regardless of who you may or may not have to collaborate with in government. Election Extra: Shinners surge, shy Fianna Fáilers and Hutch well in contention (Live From The RDS) "Our message will always remain relevant, and we as a group of politicians and activists, will always remain committed, and we'll be there waiting again,” he added. The news comes after Green Party leader Roderic O’Gorman confirmed that the party are not performing well so far and expect to retain only roughly 2 or 3 of the 12 seats the previously had. 1pm: The first count has gotten well underway with rumours that we will only get results after 3pm. 11.30am: 100pc of the boxes in Fingal West have been opened and tallied. Here are the final results: The estimated quota for Fingal West is 7,295 Sinn Féin's Louise O'Reilly is still leading the pack but will likely be just shy of making the quota on the first count. Battling it out for the two remaining seats will be Robert O'Donoghue of the Labour Party, Fine Gael's first time candidate Grace Boland and Fianna Fáil's Lorraine Clifford Lee. Final tally results for Fingal West at 11.30am 10.30am: Early tallies in Dublin Fingal West show Sinn Féin's Louise O'Reilly ahead, but with Fine Gael's and Labour's candidates close behind. Over two third of boxes have now been opened. Outgoing Green Party minister of state Joe O'Brien is currently lagging behind but he'll be hoping to see his position improve as more votes from Balbriggan are yet to be tallied. It might be a close race yet for Fine Gael’s Grace Boland and Fianna Fáil Senator Lorraine Clifford Lee. Calling it now, it looks like Louise O’Reilly might be elected on the first count, all going well for her. Fingal West tallies at 10.30am 10am: The first tallies have come in for Fingal West here is what we know so far.. Leading so far is current TD Sinn Féin’s Louise O’Reilly with 1,705 first preference votes making up 22.3pc of the total votes counted. Fine Gael’s first time candidate Grace Boland is also doing well with 1,614 first preference votes making up 19.3pc of the votes counted so far. Coming behind her then is Labour’s Robert O’Donoghue hoping to become a TD for his party with 1,536 first preference votes making up 18.4pc of the total votes counted. Also doing well is Independent candidate Tony Murphy with 11.0pc of the total votes so far. Fianna Fáil’s Lorraine Clifford Lee is doing okay with 933 first preference votes she has 10.9pc of the total votes so far Dublin's Fingal West tally at 9.45am 9am: Boxes have been opened in the National Show Centre and candidates along with tally people are watching eagerly on for some indication of where things may be going.

JC3RH-BS Type B RCCB: Advanced Circuit Protection for Modern SystemsNone

Beyond the Basics: How Infinix AI ♾️ is Challenging Apple’s Latest AI Innovations

Longtime NFL wide receiver DeSean Jackson will take over as head coach at Delaware State, Victory Formation Media and ESPN reported Thursday. If confirmed, it would be the latest data point in a growing trend of FCS football teams hiring well-known former players -- with little to no prior coaching experience -- in an effort to stand out. Jackson, 38, has no connection to Delaware State but according to ESPN, "it has always been a dream" of his to coach at an HBCU (historically black colleges and universities). Earlier this month, Norfolk State hired Michael Vick to take over the Spartans' program. Vick, who also reportedly heard from Sacramento State, hails from the Norfolk, Va., area. Norfolk State is one of Delaware State's rivals in the Mid-Eastern Athletic Conference. Colorado coach Deion Sanders spent three seasons (2020-22) as the head coach of Jackson State before moving up to the FBS level. His only prior coaching experience came at the high school level, including at his own short-lived charter school in Texas, "Prime Prep Academy." Jackson last played for the Baltimore Ravens in 2022. He is best known for two stints with the Philadelphia Eagles (2008-13, 2019-20) and played for a total of six teams in a 15-year NFL career. Jackson caught 641 passes for 11,263 yards and 58 touchdowns, adding four rushing touchdowns and four punt return touchdowns in 183 career games. Delaware State went 1-11 in 2024 (0-5 MEAC) and fired coach Lee Hull after the season. The Hornets have not had a winning season since going 6-5 in 2012. --Field Level Media

LONDON — Pooches in pullovers paraded past Buckingham Palace on Saturday for a gathering of dogs in Christmas sweaters to raise funds for rescue charities. People and dogs take part in the Rescue Dogs of London and Friends Christmas Jumper Parade on Saturday outside Buckingham Palace in central London. James Manning, PA About 130 pets, and their owners, walked Saturday from St. James's Park and along the Mall, the wide boulevard that leads to the royal palace as part of the Christmas Jumper Parade. Flossie the dog barks Saturday during the Rescue Dogs of London and Friends Christmas Jumper Parade in central London. James Manning, PA Prizes were awarded for best-dressed pets, with contenders including canine Santas, puppy elves and a French bulldog dressed in a red beret and pink jacket adorned with red bows. People and dogs take part in the Rescue Dogs of London and Friends Christmas Jumper Parade on Saturday in central London. James Manning, PA The event was organized by Rescue Dogs of London and Friends to raise money for charities that rehome dogs from overseas. People take part in the Rescue Dogs of London and Friends Christmas Jumper Parade on Saturday in central London. James Manning, PA Christmas sweater animal parades have become something of an annual tradition in London. People and dogs take part in the Rescue Dogs of London and Friends Christmas Jumper Parade on Saturday outside Buckingham Palace in central London. James Manning, PA There are more to come this year, including an event for corgis — the late Queen Elizabeth II's favorite breed — on Dec. 7 and the dachshund-friendly Hyde Park Sausage Walk on Dec 15. Named after the northern Mexican state from which it originates, the Chihuahua is the smallest dog breed and one of the oldest, with a lineage that dates as far back as the ninth century. Today, the breed makes up a remarkable 4% of all dogs in the United States and is the most popular overall in 21 states. It ranks within the top five most common breeds in 42 states in total. Requiring just 200 to 250 calories per day but boasting a lifespan of 14 to 16 years, the Chihuahua offers owners low-cost longevity and is known for its adaptability and amusing personality. Canva The French bulldog is a compact companion known for being friendly yet quiet, making it suitable for a range of lifestyles and homes. The breed has roots in the English bulldog, which was bred to a smaller size to accompany its working English owners, many of whom were artisans. As such trades closed amid the Industrial Revolution, these workers and their little bulldogs moved to France, where the breed's popularity began. The French developed a more standardized appearance which was iterated upon in the U.S. to develop the iconic bat ears. The breed has recently seen a massive increase in popularity, with AKC registrations surging by 1,000% between 2012 and 2022. Now, the French bulldog is the most popular dog in Florida, California, and Hawaii and is in the top five most common dogs in nearly half the remaining states. Branislav Nenin // Shutterstock As loyal as they are intelligent, German shepherds are among the favored breeds for guide, military, police, and search and rescue roles. The breed, which first arrived in America in the early 20th century, also enjoys peak popularity in Alaska, Montana, Wyoming, Delaware, and Pennsylvania. Athletic in nature, the breed requires lots of exercise, making them well-suited for homes with or near lots of open land. They are also well-adapted to cold temperatures and harsher climates due to their thick double coats of fur. ANNA TITOVA // Shutterstock The shih tzu, whose name means "lion" in Chinese, is king of the Empire State (New York) as well as Iowa, Rhode Island, and New Jersey. Roughly a quarter of New York state residents live in apartments, making the dog that averages 9 to 16 pounds perfect for compact households. Despite being known for its playfulness, the breed does not require much physical activity or space. The breed dates back over 1,000 years but was first brought to America surprisingly recently, following World War II. According to the American Kennel Club, every shih tzu alive today has direct lineage to just 14 shih tzus that were saved when the breed nearly went extinct during the Communist revolution. Canva Representing the best of both worlds, the golden retriever and poodle hybrid is known for its friendly, sociable demeanor and trainability. Bred to be guide dogs in the 1960s, the hybrid is not recognized as an official breed by the AKC, so there is no breed standard. Goldendoodles can thus range from mini-sized to about 90 pounds and may have fur that is curly, straight, or somewhere in between. While not official, the family-friendly dog has left paw prints all over the country, ranking in the top five most popular dogs in 37 states. In Idaho and Utah, the goldendoodle is the most popular overall. Cavan-Images // Shutterstock Maxing out at just 7 pounds, the Yorkshire terrier is the most popular breed among Maryland and Washington D.C. residents. This is not necessarily surprising considering the housing stock of the nation's capital is comprised mostly of apartment units, making the pint-sized pup perfect for metropolitans. The toy breed was bred to chase rats out of mines and mills in 19th-century England, arriving in North America in the 1870s and gaining official recognition by the AKC in 1885. Now, the breed is among the top five most common dogs in 26 states. The breed is a true terrier at heart, known for its feisty yet affectionate nature.' Additional research by Eliza Siegel. Story editing by Carren Jao. Additional editing by Kelly Glass. Copy editing by Tim Bruns. This story originally appeared on Ollie and was produced and distributed in partnership with Stacker Studio. Anna Averianova // Shutterstock From bags of kibble in the grocery store to modern home sizes, things are getting smaller—and evidently, Americans are starting to look for furry friends that match. Small breeds like terriers and toys have largely dethroned the retrievers that once dominated the most popular breed rankings. This is a continuation of a trend that began in 2022 when the Labrador retriever lost its 31-year-long streak as #1 to the French bulldog, according to the American Kennel Club. This shift may be partially attributable to the rising costs of pet products and veterinary care since smaller dogs are more economical for tighter budgets. Moreover, as remote work and nomadic living become increasingly more common, smaller dogs may appeal to those looking for pets that require less space and are easier to transport. In fact, only two sporting dog breeds are the most popular in any American state—and neither is a Labrador retriever. The most popular dog overall represents 4% of all dogs in the country—constituting over 2.3 million out of 58 million households with dogs. Ollie used data from U.S. News & World Report to further explore which dog breeds are the most popular in which states and what factors may drive residents' preferences. otsphoto // Shutterstock With webbed paws and an affinity for water, golden retrievers are lucky pups to be the favored breed of the Midwest. They are the most popular dogs in states bordering the Great Lakes—Minnesota, Wisconsin, Michigan, Illinois, and Ohio; the entirety of the New England region minus Rhode Island; plus North Dakota, Nebraska, Colorado, and Virginia. The iconic golden breed was developed in 19th-century Scotland to retrieve both from land and water during hunts, hence its swimming-related adaptations. Golden retrievers are known for their affectionate nature and eagerness to please, making them well-suited for service and other working dog roles. PeopleImages.com - Yuri A

Amid the confusion, security forces used tear gas, local news website Media Guinea reported. Many of the dead were crushed as they tried to escape through the stadium gates, a journalist covering the game for a local sports website told The Associated Press. “The gates, that’s where the stampede happened,” said Cissé Lancine, who got away by climbing over one of the stadium walls. “I was saved because I did not rush towards the exit." The world's latest sports crowd disaster unfurled Sunday in the second-largest city in a military-run nation where information is sparse and government-controlled at the best of times. It was not immediately clear how much the death toll could grow. Lancine said between 20,000 and 30,000 people were present at the Third of April stadium to watch the local Labe and Nzerekore teams compete in the final of the first national tournament honoring military leader Mamadi Doumbouya. Checkpoints were set up Monday throughout Nzerekore, a city of about 200,000 that was at a standstill as soldiers guarded the hospital where victims were being treated. Most shops were closed. Video, apparently from the scene, showed shouting fans protesting the refereeing. People ran as they tried to escape the stadium, many of them jumping the high fence. “Supporters threw stones. This is why the security services used tear gas,” reported Media Guinea, which also wrote that several of the dead were children and some of the injured were in critical condition. The footage showed people lying on the floor of a hospital as members of a crowd helped the wounded. Enock Loua, a resident of Nzerekore, learned over the phone that his niece Aline Olivier had been killed. "We have a hard time realizing what happened to us, it is as if the sky has fallen on our heads,” Loua told The Associated Press. Authorities are trying to establish who was responsible, Prime Minister Amadou Oury Bah said on national television. The National Alliance for Alternation and Democracy opposition coalition said the tournament was organized to drum up support for Doumbouya's “illegal and inappropriate” political ambitions. Doumbouya, who ousted then-President Alpha Conde in 2021 , has been eyeing a possible run for the presidential election, for which the date has not been set. The transition charter put in place by his own regime does not allow him to run. Guinea is one of a number of West African countries — including Mali, Niger and Burkina Faso — where the military has taken power and delayed a return to civilian rule. Doumbouya said he was preventing the country from slipping into chaos and chastised the previous government for broken promises. He has, however, been criticized for not meeting the expectations that he raised. Guinea’s leader announced three days of national mourning starting on Tuesday, in a presidential decree read on national television.

Astro Zindagi: Weekly HoroscopeANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.

Delaware judge reaffirms ruling that invalidated massive Tesla pay package for Elon Musk

None

Previous: slot jili
Next: 49jili slot